Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$29.58 USD
+2.58 (9.54%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $29.80 +0.22 (0.74%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Brokerage Reports
Cassava Sciences, Inc. [SAVA]
Reports for Purchase
Showing records 1 - 20 ( 135 total )
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 092324
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 091424
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 82424
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Is That Light at the End of the Tunnel? Reiterate Neutral Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 81124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 8124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 72124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Executive Leadership Changes; Reiterate Neutral Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 71124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Former Scientific Advisor Charged With Fraud; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 62124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 61124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 6124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 52124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
1Q24 Results: First Phase 3 Readout on Track for YE24; Reiterate Buy; Raise PT to $131
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 51124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 5124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 42124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
DSMB Greenlights Continuing Simufilam Phase 3 Trials; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 41124
Provider: Stock Traders Daily
Analyst: Research Department